Last updated on: 06/01/2014
Name of organisation
1) Department/Research groupDivision of Pharmacoepidemiology & Clinical Pharmacology
2) Organisation/affiliationUtrecht Institute for Pharmaceutical Sciences
Short Name in the inventoryUtrecht University Pharmacoepidemiology Center
Administrative Contact
Title Mrs
Last name Dinzey
First name Ineke
Address line 1Universiteitsweg 99
Address line 2PO Box 80082
Address line 3
CityUtrecht
Postcode3508 TB
CountryNetherlands
Phone number (incl. country code)31-30-2537324
Alternative phone number
Fax number (incl. country code)31-30-2539166
Scientific Contact
Title Dr
Last name Klungel
First name Olaf
Address line 1Universiteitsweg 99
Address line 2PO Box 80082
Address line 3
CityUtrecht
Postcode3508 TB
CountryNetherlands
Phone number (incl. country code)31-6-28831313
Alternative phone number
Fax number (incl. country code)31-30-2539166
2. Description
The Utrecht University Pharmacoepidemiology Center is one of the leading academic groups in the world in the interface between pharmacoepidemiology, pharmacovigilance and drug innovation. The group has an extensive research record on new methods of data collection, study design and data analysis delivering >50 papers per year. Key features of the profile of the group over the years have been new methods on drug channelling, exposure ascertainment, rare events, signal detection and evaluation, adjustment for confounding, record linkage,pharmacogenetics and implication for public health and weighing of benefit/risk.
3. Category
University based
4. Available resources
In houseVia Contacts/Network
Epidemiologist/Pharmacoepidemiologist
Yes
No
Statistician
Yes
No
Clinician
No
Yes
Clinical Pharmacologist
Yes
No
Pharmacist
Yes
No
Geneticist/Pharmacogeneticist
Yes
No
IT specialist
Yes
No
Ethics expertise
No
Yes
Legal expertise
Yes
No
Regulatory expertise
Yes
No
5. Therapeutic/disease areas of research in drug safety/risk-benefit performed in the past 5 years
Cardiovascular diseases
Disorders of the central nervous system
Endocrine disorders
Geriatrics
Liver disease
Musculoskeletal and joint diseases
Osteoporosis
Paediatrics
Psychiatry
Respiratory diseases
6. Design of drug safety/risk-benefit studies published in the past 5 years
Cohort Study
Case Control Study
Drug Utilisation
Meta-Analysis
7. Experience in collecting data directly from individual patients/respondents
Number of Studies
Greater than 5
Number of patients/respondents involved in the study(ies)
Greater than 15000
8. Access to data collection resources
Capacity to conduct face-to-face interviews
Yes
In a clinic
Yes
In the community
Yes
Electronic data capture systems
Yes
System used:
Mondriaan
Interactive voice response systems
No
Call centre
No
9. Experience in secondary research and meta-analysis
Yes
10. Work with existing data resources in the past 3 years
Name of data resourceNo. of studies
PHARMO34
CPRD20
WHO Vigibase/LAREB (national system)8
Hospital/Institution based47
Mondriaan (several linked databases)10
11. Registries established by centre
Disease Registrymyocardial infarction, diabetes, DILI, Astma in children, Fractures, CAP, medication errors and hospitalizations
12. Experience in collaboration in a study team
Principal Investigator
Collaborating Investigator
13. Current involvement in research networks
Networks registered with ENCePP
CARING
PROTECT
Other networks:
Network nameNationalInternationalLink to webpage
14. Interest in research opportunities which are funded
By pharmaceutical companies
By charities
By government
By research councils
15. Interest in contract research only if free to publish results
Yes
16. Selected publications of the last 5 calendar years
ReferenceLink to web-publication
F. de Vries, et al. Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. Int J Epidemiol 2006;35:1301-8.
Verhoef TI, et al.; the EU-PACT Group. A Randomized Trial of Genotype-Guided
Dosing of Acenocoumarol and Phenprocoumon. N Engl J Med. 2013 Nov 19. [Epub ahead of print]
Belitser SV, et al.
Measuring balance and model selection in propensity score methods. Pharmacoepidemiol Drug Saf. 2011;20:1115-29.
H. Gardarsdottir, et al. Duration of antidepressant drug treatment and its influence on risk of relapse/recurrence: immortal and neglected time bias. Am J Epidemiol 2009;170:280-5.
A.J. Leendertse, et al. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008;168:1890-6.
